Last checked at 23 May 2019 14:35
Cambridge Cognition Holdings Plc
('Cambridge Cognition' or the 'Company')
Result of AGM and Board Changes
Cambridge Cognition Holdings plc ("the Company"), which develops and markets neuroscience technology to assess brain health, held its Annual General Meeting ("AGM") at 10.00am at the registered office of the Company, Tunbridge Court, Tunbridge Lane, Bottisham, Cambridge, CB25 9TU. All resolutions put to the AGM were duly passed.
Confirmation of Board Changes
Michael Lewis and Nicholas Kerton did not offer themselves for re-election as Non-Executive Directors of the Company and therefore retire from the Board by rotation.
Steven Powell has stepped down as Chief Executive Officer of the Company and his appointment as a Non-Executive Director and as Chairman of the Board of Directors was confirmed at the AGM. In addition to his Chairman duties Steven will continue to play a significant role in key long-term corporate and R&D strategies of the Company.
Matthew Stork, the Company's recently appointed Chief Operating Officer, has joined the Board as Chief Executive Officer. He has expertise in a broad range of healthcare sectors including healthcare IT (including AI), diagnostic imaging, clinical service delivery and pharmaceuticals. He has held executive roles at the InHealth Group, General Electric, ArjoHuntleigh, Canon Medical Systems (formerly Toshiba Medical Systems) and Smith & Nephew. Further information on his appointment is set out below.
The Company will seek to appoint an additional independent Non-Executive Director within the next two months.
Enquiries
Cambridge Cognition Holdings PLC Steven Powell, Chief Executive Officer Matthew Stork, Chief Operating Officer |
Tel: 01223 810 700 press@camcog.com |
finnCap Ltd (NOMAD and Joint Broker) Geoff Nash / Simon Hicks Alice Lane/Manasa Patil | Tel: 020 7220 0500 (Corporate Finance) (ECM) |
Dowgate Capital Limited (Joint Broker) David Poutney / James Serjeant | Tel: 020 3903 7715
|
IFC Advisory Ltd (Financial PR and IR) Graham Herring / Miles Nolan / Zach Cohen | Tel: 020 3934 6630
|
About Cambridge Cognition
Cambridge Cognition is a neuroscience technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early, and reduce global R&D and healthcare costs.
For further information visit www.cambridgecognition.com
The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies:
Matthew William Stork (aged 50) has been a director of the following companies during the five years preceding the date of this announcement:
Current directorships
MIH Holdings Limited
Previous directorships
n/a
There is no further information to be disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies.